In addition, tofogliflozin (sodium-glucose cotransporter 2 inhibitor) is the drug used to treat T2DM and it reduces the risk of CRC through attenuation of chronic inflammation, hyperglycemic state and IGF/IGF-1R axis activation in obesity and diabetes mice [27]. This evidence concerns the gene IGF1 and diabetes mellitus.